RxDoctor Payments Data

Patricia Gasper

Family · South Bend, INNPI 1942650726

Payments from drug & device makers

$2,318in general payments, 2019–2025

Across 73 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$308
  • Abbott$305
  • Medtronic$293
  • Novartis$287
  • Inspire Medical Systems, Inc.$257
  • Pfizer$139
  • plus $728 from 17 others

What the payments were for

  • Food & beverage$2,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,318 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$72,156
Medicare patients
457
Services billed
1,218

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban242$278,993
XareltoRivaroxaban58$64,837
EntrestoSacubitril/Valsartan41$48,954
JardianceEmpagliflozin15$8,930
Dofetilide70$8,720
Propafenone Hcl ErPropafenone Hcl19$3,662
Metoprolol Succinate304$3,639
Potassium Chloride219$3,513
Flecainide Acetate69$2,930
Ranolazine ErRanolazine16$1,676
Torsemide67$1,179
Amiodarone Hcl73$1,121
Atorvastatin Calcium115$1,096
Valsartan48$1,034
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$278,993242 claims
Johnson & JohnsonXarelto$96$64,83758 claims
NovartisEntresto$287$48,95441 claims
Boehringer IngelheimJardiance$18$8,93015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in South Bend

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →